Ken Persen Named Chief Technology Officer at HeartBeam

HeartBeam Inc. has welcomed a new executive team member.

The company recently appointed Ken Persen as chief technology officer. Persen has extensive technology, executive and startup experience in healthcare and cardiac device industries. He leads the overall technology strategy and development of the HeartBeam AIMI and HeartBeam AIMIGo platforms.
 
“I am very excited to join the HeartBeam team and lead the development of the first-of-its-kind remote 3D vector electrocardiogram technology,” said Persen. “The promise of HeartBeam’s technology to substantially change the way that patients and healthcare professionals manage heart attack symptoms is even more compelling.”
 
Persen has more than 25 years of experience in the digital healthcare and cardiac device industries. Most recently, Persen founded LIVMOR Inc. a digital health company, where he served as chief technology officer. Persen began his career in the cardiac rhythm device industry in software engineering and development roles with Guidant Corporation and Cameron Health, both subsequently acquired by Boston Scientific Corp., and then held leadership roles with medical informatics instruments and systems delivering electronic medical care, before founding LIVMOR.
 
“We are very pleased to welcome Ken onto our leadership team,” said Branislav Vajdic, Ph.D., HeartBeam CEO and founder. “He brings a deep knowledge of innovation and technology, combined with industry insights, which will support continued development and evolution of HeartBeam’s technology.”
 
HeartBeam Inc. is a development stage digital healthcare company with proprietary ECG telemedicine technology that redefines the way high-risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack.